Markets:

Overview

News

Currencies

International

Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

5.340 -0.180 (-3.26%)

Streaming Delayed Price Updated: 10:33 AM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Marijuana Stock Movers For August 2, 2023 ↗

August 02, 2023

Via Benzinga

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

August 01, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

August 01, 2023

From SciSparc Ltd

Via GlobeNewswire

EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio ↗

August 01, 2023

Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of...

Via Benzinga

Cannabis Stock Gainers And Losers From July 25, 2023 ↗

July 25, 2023

Via Benzinga

Marijuana Stock Movers For July 31, 2023 ↗

July 31, 2023

Via Benzinga

SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

July 14, 2023

From SciSparc Ltd

Via GlobeNewswire

Cannabis Stock Gainers And Losers From July 28, 2023 ↗

July 28, 2023

Via Benzinga

SciSparc To Conduct Clinical Trial For Dronabinol-Based Drug To Treat Tourette Syndrome In Germany ↗

July 03, 2023

SciSparc Ltd. (NASDAQ: SPRC) has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany (“BfArM”) for its phase IIb clinical trial to use SCI-110 for treating...

Via Benzinga

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

June 30, 2023

From SciSparc Ltd

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

June 28, 2023

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on!

Via InvestorPlace

SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome

June 21, 2023

From SciSparc Ltd

Via GlobeNewswire

EXCLUSIVE: SciSparc's Tourette Syndrome Candidate Receives IRB Approval To Start Phase 2b Study In US ↗

June 21, 2023

SciSparc Ltd (NASDAQ: SPRC) has received Institutional Review Board (IRB) approval for its Phase 2b clinical trial for SCI-110 in subjects suffering from Tourette Syndrome. Tourette Syndrome is a...

Via Benzinga

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

June 16, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

June 16, 2023

From SciSparc Ltd

Via GlobeNewswire

Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome ↗

June 16, 2023

Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:CMND) (FSE:CWY) announced that as part of the company's ongoing collaboration with SciSparc Ltd.

Via Benzinga

The 7 Most Promising Penny Stocks to Buy in June ↗

June 07, 2023

These top penny stocks for June look to have legitimate catalysts that can certainly send share prices higher.

Via InvestorPlace

SciSparc Nutraceuticals Granted An Exclusive License For The Sales Of CannAmide On The Amazon Marketplace In Canada ↗

June 07, 2023

Jeffs' Brands Ltd (NASDAQ: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, announced that SciSparc Nutraceuticals Inc., in which the company owns a 49% equity interest, has...

Via Benzinga

Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada

June 07, 2023

From Jeffs' Brands Ltd

Via GlobeNewswire

SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals

June 07, 2023

From SciSparc Ltd

Via GlobeNewswire

Why A National Cannabis Organization Sacked Half Its Staff, CEO Turnovers And More Exec Changes ↗

June 05, 2023

NCIA Sacks Half Of Its Team To Increase Financial Strength

Via Benzinga

Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 02, 2023

Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group.

Via Benzinga

New Drug Based On FDA-Approved Synthetic THC And CannAmide Shows Promise In Treating Agitation In Alzhemier's ↗

June 02, 2023

SciSparc Ltd.

Via Benzinga

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

June 02, 2023

Topline results using the Company's SCI-110 met the trial’s primary and secondary end points, demonstrating high safety profile and reduced agitation

From SciSparc Ltd

Via GlobeNewswire

SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

May 30, 2023

From SciSparc Ltd

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

May 08, 2023

Pre-market stock movers are a hot topic on Monday as we dive into the biggest winners and losers traders need to know about this morning!

Via InvestorPlace

SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program

May 08, 2023

From SciSparc Ltd

Via GlobeNewswire

SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation

May 02, 2023

From SciSparc Ltd

Via GlobeNewswire

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗

April 24, 2023

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...

Via Benzinga

Why SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

April 21, 2023

Gainers Mangoceuticals, Inc. (NASDAQ: MGRX) shares jumped 207% to $2.84. The company announced Thursday, that it's featured on Webull Corporate Communications Service Platform.

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.